Member Exclusive

Cancer drug development halted following trial deaths

Mirna Therapeutics Inc. (Austin, TX, USA) halts drug development of its flag-ship oncology drug MRX34 following adverse trial results, culminating with the deaths of clincal trial participants.

Go to the profile of MedChemNet
Nov 16, 2016
1
0

Please sign in or register for FREE

Register to MedChemNet

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.

Register

No comments yet.